Commercialising Products and Technologies

Our strategy is to market our products through other pharmaceutical companies with the capability of launching our products into major territories. Our products and technologies are:

COLAL-PRED^®
Alizyme has licensed the rights to develop and commercialise COLAL-PRED^® in Europe, South Africa, Australia and New Zealand to Norgine BV. The North American rights to COLAL-PRED^® have been licensed to Prometheus Laboratories Inc. Alizyme has entered into a strategic partnership with TSD Japan Inc for the development of COLAL-PRED^® in Japan. It is currently in Phase I development in Japan and Phase II development in the US.

ATL-104
ATL-104 has completed Phase IIa clinical development to evaluate it for the treatment of mucositis, a side effect of cancer treatment.

COLAL^®
Alizyme is interested in co-developments involving its colonic drug delivery system, COLAL^®, for the delivery of drugs to the colon for local action or for systemic delivery.



(Note: COLAL^® and COLAL-PRED^® are registered trademarks of Alizyme Therapeutics Limited)